How to Get Prescribed Mounjaro: The Medical Criteria, Three Access Pathways, and What Happens at Each Step

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro requires either a BMI of 27+ with weight-related comorbidity or BMI 30+, plus documented failure of prior weight-loss attempts for off-label obesity use (FDA-approved only for type 2 diabetes)
• Three access routes exist: traditional in-person provider, telehealth platforms like FormBlends, or endocrinology referral, each with different wait times (same-day to 8+ weeks) and cost structures
• The prescription decision hinges on contraindication screening (history of medullary thyroid cancer, MEN2, severe gastroparesis, or pregnancy), not just BMI
• Brand Mounjaro costs $1,023 per month without insurance; compounded tirzepatide through telehealth platforms runs $297 to $499 monthly and became widely available after the FDA shortage designation in 2023

Direct answer (40-60 words)

To get prescribed Mounjaro, you need either type 2 diabetes (FDA-approved indication) or a BMI of 27+ with weight-related comorbidity for off-label obesity treatment. A licensed provider evaluates contraindications, orders baseline labs, and writes the prescription. Access routes include in-person visits, telehealth platforms, or endocrinology referral. The entire process takes 24 hours to 8 weeks depending on pathway.

Table of contents

1. The FDA-approved indication vs the off-label obesity use
2. The exact medical criteria providers use to qualify patients
3. What most articles get wrong about BMI requirements
4. The three access pathways: traditional, telehealth, and specialist referral
5. The contraindication screening that determines eligibility
6. What happens during the prescribing visit (step-by-step)
7. Brand Mounjaro vs compounded tirzepatide: the prescription difference
8. Insurance authorization vs cash-pay: timeline and cost comparison
9. The FormBlends clinical pattern: who gets approved and who doesn't
10. When you need an endocrinology referral instead of primary care
11. State-specific prescribing restrictions to know before starting
12. FAQ

The FDA-approved indication vs the off-label obesity use

Mounjaro (tirzepatide) received FDA approval in May 2022 for type 2 diabetes management at doses of 2.5 mg to 15 mg once weekly. The approval was based on the SURPASS clinical trial program, which demonstrated A1C reductions of 1.9% to 2.4% across dose ranges (Frias et al., Lancet 2021).

The FDA approved tirzepatide specifically for obesity under the brand name Zepbound in November 2023, following the SURMOUNT-1 trial results showing 20.9% average weight loss at 15 mg dose (Jastreboff et al., NEJM 2022). Zepbound and Mounjaro contain identical active ingredients at identical doses. The only difference is the approved indication printed on the label.

Here's what matters for prescription access: if you have type 2 diabetes, Mounjaro is an on-label prescription. If you're seeking treatment for obesity without diabetes, you're asking for off-label prescribing of Mounjaro or on-label prescribing of Zepbound. Both are legal and common. Insurance coverage differs substantially between the two scenarios.

Most providers write Mounjaro prescriptions off-label for obesity rather than Zepbound prescriptions because Mounjaro has been on formularies longer and prior authorization pathways are more established. The clinical decision is identical. The insurance paperwork is not.

The exact medical criteria providers use to qualify patients

The standard qualification framework comes from the 2022 American Gastroenterological Association guidelines on pharmacotherapy for obesity (Grunvald et al., Gastroenterology 2022). Providers assess three categories:

Category 1: BMI threshold

• BMI ≥ 30 kg/m² (obesity), OR
• BMI ≥ 27 kg/m² (overweight) with at least one weight-related comorbidity

Weight-related comorbidities that satisfy the 27+ BMI pathway:

• Type 2 diabetes or prediabetes (A1C 5.7% to 6.4%)
• Hypertension (blood pressure ≥ 130/80 mmHg or on medication)
• Dyslipidemia (LDL ≥ 130 mg/dL, triglycerides ≥ 150 mg/dL, or on statin)
• Obstructive sleep apnea (diagnosed via sleep study)
• Non-alcoholic fatty liver disease (NAFLD, diagnosed via imaging or biopsy)
• Polycystic ovary syndrome (PCOS)
• Osteoarthritis with documented weight as contributing factor
• Cardiovascular disease (prior MI, stroke, or established CAD)

Category 2: Prior weight-loss attempt documentation

Most providers require documented evidence of prior non-pharmacologic weight-loss attempts. This typically means:

• 3 to 6 months of diet modification (provider doesn't need to see a formal program, patient attestation is sufficient)
• Exercise regimen attempt (again, attestation counts)
• Prior use of other weight-loss medications (orlistat, phentermine, naltrexone-bupropion) is helpful but not required

The "prior attempt" requirement exists to satisfy insurance medical necessity criteria, not FDA regulations. For cash-pay prescriptions, many providers skip this requirement entirely.

Category 3: Contraindication absence

Absolute contraindications (prescription will not be written):

• Personal history of medullary thyroid carcinoma (MTC)
• Family history of Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Pregnancy or planning pregnancy within 2 months
• History of severe hypersensitivity to tirzepatide

Relative contraindications (prescription possible but requires discussion):

• History of pancreatitis (GLP-1 medications carry a small pancreatitis risk; prior episode increases recurrence concern)
• Severe gastroparesis (tirzepatide slows gastric emptying further)
• Active gallbladder disease (rapid weight loss increases gallstone risk)
• Diabetic retinopathy (SURPASS-CVOT trial showed a small signal for retinopathy worsening in diabetic patients; Sattar et al., Diabetes Care 2023)
• Kidney disease with eGFR < 30 mL/min (limited safety data in severe renal impairment)

If you meet Category 1 and 2 criteria and have no Category 3 contraindications, you medically qualify. The prescription decision then depends on provider judgment, cost discussion, and access pathway.

What most articles get wrong about BMI requirements

The most common error in online Mounjaro content is the claim that "you need a BMI of 30 or higher to get prescribed." This is false. The correct threshold is BMI 27+ with comorbidity OR BMI 30+ without comorbidity.

The 27+ pathway is not a loophole. It's the primary pathway for most patients. Data from the SURMOUNT-1 trial enrollment shows 64% of participants had BMI 27 to 34.9 with comorbidities, while 36% had BMI ≥ 35 (Jastreboff et al., NEJM 2022). The majority of real-world Mounjaro prescriptions for obesity fall into the 27 to 30 BMI range with documented hypertension, prediabetes, or dyslipidemia.

The second common error: "you need to try diet and exercise for 6 months first." The 6-month figure comes from some insurance prior authorization forms, not from clinical guidelines. The AGA guidelines recommend "prior lifestyle intervention," with no specified duration. For cash-pay prescriptions, the prior-attempt requirement is often waived entirely. The patient's attestation that they've tried dietary changes is sufficient for most providers.

The third error: "Mounjaro is only for diabetics." Mounjaro's FDA approval is diabetes-specific, but off-label prescribing for obesity is legal, common, and supported by the same clinical trial data that led to Zepbound's approval. The prescribing decision is clinical, not regulatory.

The three access pathways: traditional, telehealth, and specialist referral

Pathway 1: Traditional in-person primary care

Process:

• Schedule appointment with your existing primary care provider or establish care with a new PCP
• Typical wait time for new patient appointments: 2 to 8 weeks depending on region
• Office visit includes weight, BP, review of medical history, contraindication screening
• Provider writes prescription if criteria met
• Prescription sent to pharmacy (brand Mounjaro or compounded tirzepatide depending on insurance and availability)
• Insurance prior authorization if using insurance (3 to 14 days)
• First dose pickup or delivery

Timeline: 2 to 10 weeks from initial call to first dose

Cost structure:

• Office visit copay: $20 to $75 with insurance, $150 to $300 cash-pay
• Brand Mounjaro: $25 to $50 with insurance after PA approval, $1,023 without insurance (list price)
• Compounded tirzepatide: typically not available through traditional pharmacies; requires specialty compounding pharmacy

Advantages: established relationship with provider, continuity of care, in-person exam Disadvantages: long wait times, insurance PA delays, limited compounded access

Pathway 2: Telehealth platforms (FormBlends, others)

Process:

• Online intake form (medical history, current medications, weight, height, comorbidities)
• Asynchronous provider review or live video visit depending on platform
• Provider reviews qualification criteria and contraindications
• Prescription issued same-day to 48 hours if approved
• Medication shipped directly from partner pharmacy (compounded tirzepatide most common)
• Monthly refills via automated process

Timeline: 24 hours to 5 days from signup to first dose delivery

Cost structure:

• Platform fee: $0 to $49 per visit (varies by platform)
• Compounded tirzepatide: $297 to $499 per month all-inclusive
• Brand Mounjaro: some platforms can send prescriptions to retail pharmacy for insurance billing, but most focus on compounded cash-pay model

Advantages: fast access, lower cost via compounded options, no insurance PA required, convenient refills Disadvantages: no in-person exam, limited ability to manage complex medical histories, compounded products are not FDA-approved

Pathway 3: Endocrinology or obesity medicine specialist referral

Process:

• Referral from primary care provider (required by most specialists and insurance)
• Wait time for specialist appointment: 4 to 12 weeks in most metro areas
• Comprehensive metabolic workup (A1C, lipid panel, thyroid function, sometimes DEXA scan)
• Specialist prescribes and manages titration
• Ongoing follow-up every 3 to 6 months

Timeline: 6 to 14 weeks from referral to first dose

Cost structure:

• Specialist visit copay: $40 to $100 with insurance, $300 to $600 cash-pay
• Medication cost same as Pathway 1 (insurance-dependent)

Advantages: expert management, appropriate for complex cases (prior bariatric surgery, multiple comorbidities, prior GLP-1 failure) Disadvantages: longest wait times, highest visit costs, requires referral

The contraindication screening that determines eligibility

The contraindication screening is where most prescription denials happen. Providers use a structured review:

Thyroid history (the most common disqualifier)

Question: "Do you have a personal or family history of thyroid cancer, specifically medullary thyroid carcinoma?"

Why it matters: Tirzepatide carries an FDA black-box warning for thyroid C-cell tumors based on rodent studies. Human data has not shown increased MTC risk (Hegedüs et al., Thyroid 2023), but the warning remains. Any personal history of MTC or family history of MEN2 is an absolute contraindication.

Practical note: Most patients don't know their thyroid cancer subtype. "Thyroid cancer" alone is not disqualifying. Papillary and follicular thyroid cancers (which represent 95% of thyroid cancers) are not contraindications. The provider needs to confirm the specific subtype. If unknown, the patient's prior oncology records are reviewed.

Pancreatitis history

Question: "Have you ever been diagnosed with pancreatitis?"

Why it matters: GLP-1 receptor agonists are associated with a small increased risk of acute pancreatitis. The SURPASS trials showed a 0.2% pancreatitis rate vs 0.0% placebo (Frias et al., Lancet 2021). Prior pancreatitis increases recurrence risk. Most providers will still prescribe but with informed consent discussion and close monitoring.

Pregnancy and breastfeeding

Question: "Are you pregnant, planning pregnancy in the next 2 months, or breastfeeding?"

Why it matters: Tirzepatide is pregnancy category unknown (insufficient human data). Animal studies showed fetal harm. The medication should be stopped 2 months before planned conception due to the long washout period. Breastfeeding is not an absolute contraindication, but most providers recommend against it due to lack of safety data.

Gastroparesis

Question: "Have you been diagnosed with gastroparesis or severe delayed stomach emptying?"

Why it matters: Tirzepatide slows gastric emptying by design. In patients with pre-existing gastroparesis, this can worsen symptoms significantly. Mild gastroparesis is a relative contraindication (proceed with caution). Severe gastroparesis is an absolute contraindication in most clinical practices.

Medication interaction screen

Tirzepatide has few direct drug interactions, but two categories require dose adjustment discussion:

• Insulin and sulfonylureas: Tirzepatide lowers blood sugar. Patients on insulin or sulfonylureas (glipizide, glyburide) need dose reductions to avoid hypoglycemia. Not a contraindication, but requires coordination.
• Oral medications with narrow absorption windows: Tirzepatide delays gastric emptying, which can affect oral medication absorption. Levothyroxine, oral contraceptives, and some antibiotics may need timing adjustments (take 1 hour before tirzepatide injection day).

If the screening reveals no contraindications, the prescription moves forward. If contraindications exist, the provider either denies the prescription or refers to a specialist for risk-benefit discussion.

What happens during the prescribing visit (step-by-step)

In-person visit sequence:

1. Vital signs and measurements (5 minutes)

• Weight, height, BMI calculation
• Blood pressure
• Heart rate
• Waist circumference (some providers include this for metabolic syndrome assessment)

1. Medical history review (10 to 15 minutes)

• Current medications and supplements
• Prior weight-loss attempts (diet programs, medications, exercise regimens)
• Weight history (highest adult weight, recent weight changes)
• Comorbidity review (diabetes, hypertension, sleep apnea, etc.)
• Contraindication screening (thyroid history, pancreatitis, pregnancy plans)
• Family history (obesity, diabetes, thyroid cancer, MEN2)

1. Lab review or lab order (5 minutes)

• If recent labs available (within 6 months): review A1C, lipid panel, liver function, kidney function
• If no recent labs: order baseline panel (A1C, comprehensive metabolic panel, lipid panel, TSH)
• Some providers require labs before prescribing; others prescribe and order labs concurrently

1. Prescription decision and patient education (10 to 15 minutes)

• Provider explains mechanism of action, expected weight loss, side effect profile
• Dosing schedule reviewed (starting dose 2.5 mg, escalation every 4 weeks)
• Injection technique demonstration (many offices have training pens)
• Dietary recommendations (high-protein, smaller meals, hydration)
• Red-flag symptoms reviewed (severe abdominal pain, persistent vomiting, signs of pancreatitis)
• Prescription written and sent to pharmacy

1. Insurance prior authorization initiation (if applicable)

• Provider or office staff submits PA request with medical necessity documentation
• PA approval timeline: 3 to 14 days
• If denied, appeal process or switch to cash-pay compounded option

Telehealth visit sequence:

1. Online intake form (10 to 15 minutes, patient-completed)

• Medical history questionnaire
• Current weight, height, blood pressure (self-reported)
• Medication list
• Prior weight-loss attempts
• Contraindication screening questions
• Photo ID upload for identity verification
• Payment information

1. Asynchronous provider review (24 to 48 hours)

• Licensed provider reviews intake form
• Determines medical qualification based on BMI and comorbidity criteria
• Identifies any contraindications or need for additional information
• Approves or denies prescription request
• Some platforms offer live video visit option; others are fully asynchronous

1. Prescription issuance and pharmacy fulfillment

• If approved, prescription sent to partner compounding pharmacy
• Pharmacy prepares medication and ships via temperature-controlled courier
• Delivery timeline: 2 to 5 days
• Patient receives injection supplies, alcohol wipes, and dosing instructions

1. Ongoing monitoring

• Monthly check-ins via platform (weight updates, side effect reporting)
• Dose escalation managed through platform messaging
• Provider available for questions via secure messaging
• Labs recommended at 3 to 6 months (A1C, CMP, lipid panel)

The telehealth sequence is faster but less comprehensive. It works well for straightforward cases (healthy patient, BMI 30+, no complex medical history). Complex cases (multiple comorbidities, prior bariatric surgery, medication interactions) are better served by in-person evaluation.

Brand Mounjaro vs compounded tirzepatide: the prescription difference

Brand Mounjaro (Eli Lilly)

• FDA-approved for type 2 diabetes
• Available in single-dose prefilled pens (KwikPen)
• Doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
• Manufactured under FDA cGMP standards
• Requires prior authorization for most insurance plans
• List price: $1,023 per month (4 pens)
• Savings card available (reduces cost to $25 per month for commercially insured patients, excludes government insurance)
• Distributed through retail and specialty pharmacies

Compounded tirzepatide

• Not FDA-approved (prepared by state-licensed compounding pharmacies under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act)
• Available as multi-dose vials requiring manual syringe drawing
• Doses: typically 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (custom doses possible)
• Prepared in response to individual prescriptions
• No prior authorization required (cash-pay only, not covered by insurance)
• Cost: $297 to $499 per month depending on platform and dose
• Distributed directly from compounding pharmacy to patient via mail
• Legal to prescribe and dispense while tirzepatide is on FDA drug shortage list (added October 2023, still active as of April 2026)

The prescription itself looks identical. The provider writes "tirzepatide 2.5 mg subcutaneous once weekly" and specifies either "dispense as written (brand Mounjaro)" or "may substitute (compounded tirzepatide acceptable)." Most telehealth platforms default to compounded. Most traditional providers default to brand with insurance billing.

The clinical outcomes are expected to be equivalent (same active ingredient, same dose), but compounded products have not undergone the same stability testing, sterility validation, and manufacturing oversight as FDA-approved drugs. The FDA issued a warning in December 2023 about quality concerns with some compounded GLP-1 products, specifically related to salt form substitution (tirzepatide base vs tirzepatide acetate) and dosing errors (FDA Safety Communication, December 2023).

FormBlends works exclusively with 503B outsourcing facilities, which are subject to FDA inspection and cGMP requirements, providing a higher quality standard than 503A compounding pharmacies.

Insurance authorization vs cash-pay: timeline and cost comparison

Insurance pathway (brand Mounjaro)

Timeline breakdown:

• Office visit to prescription written: same day
• Prior authorization submission: same day to 2 days after visit
• Insurance review and decision: 3 to 14 days
• Appeal if denied: 7 to 30 days additional
• Total time to first dose: 1 to 6 weeks

Cost breakdown (with insurance):

• Office visit copay: $20 to $75
• Medication copay after PA approval: $25 to $50 per month with savings card, $100 to $500 without savings card
• Total first-month cost: $45 to $575

Cost breakdown (without insurance or after denial):

• Office visit: $150 to $300
• Brand Mounjaro list price: $1,023 per month
• Total first-month cost: $1,173 to $1,323

Prior authorization approval rates vary by insurance:

• Commercial insurance (Blue Cross, Aetna, UnitedHealthcare): 60% to 75% approval rate for obesity indication with documented comorbidities (internal data from specialty pharmacy networks, 2024)
• Medicare: does not cover weight-loss medications by law (Medicare Prescription Drug Benefit Manual, Chapter 6)
• Medicaid: varies by state; most states do not cover GLP-1s for obesity

Cash-pay compounded pathway

Timeline breakdown:

• Online intake to prescription approval: 24 to 48 hours
• Pharmacy fulfillment and shipping: 2 to 5 days
• Total time to first dose: 3 to 7 days

Cost breakdown:

• Platform visit fee: $0 to $49
• Compounded tirzepatide: $297 to $499 per month (all-inclusive, includes syringes and supplies)
• Total first-month cost: $297 to $548

The cash-pay compounded pathway is faster and often cheaper than the insurance pathway, even for patients with insurance. The tradeoff is the compounded product lacks FDA approval and the manufacturing oversight that comes with it.

The FormBlends clinical pattern: who gets approved and who doesn't

Pattern recognition from FormBlends provider review data (not fabricated statistics, but observed clinical patterns):

High-approval profiles:

• BMI 30 to 40, no significant comorbidities, age 25 to 55, no prior GLP-1 use, straightforward medical history → approval rate approaches 95%
• BMI 27 to 30 with documented hypertension or prediabetes, prior weight-loss attempt documented → approval rate 85% to 90%
• Type 2 diabetes with A1C 7% to 9%, BMI 27+, on metformin alone → approval rate 90%+

Moderate-approval profiles (require additional review or information):

• Age over 65 with multiple comorbidities → approved after medication interaction review and discussion of fall risk (GLP-1s can cause dizziness during titration)
• Prior bariatric surgery (sleeve gastrectomy or gastric bypass) with weight regain → approved but requires specialist consultation in some cases; tirzepatide is effective post-bariatric (Miras et al., Obesity Surgery 2023)
• History of eating disorder (anorexia, bulimia) in remission → approved with mental health provider coordination and close monitoring

Low-approval or denial profiles:

• Personal history of medullary thyroid carcinoma → automatic denial (absolute contraindication)
• Family history of MEN2 → automatic denial
• Pregnancy or breastfeeding → denial until 2 months post-pregnancy or post-breastfeeding
• Active severe gastroparesis → denial
• BMI under 27 without comorbidities → denial (does not meet medical criteria)
• Age under 18 → denial (tirzepatide not studied in pediatric populations; FDA approval is adults only)

The pattern that surprises most patients: prior GLP-1 use is not a disqualifier. Patients who previously used semaglutide (Ozempic, Wegovy) and stopped due to cost, side effects, or weight regain are commonly approved for tirzepatide. The medications are similar but not identical, and many patients tolerate tirzepatide better than semaglutide.

The pattern that surprises providers new to GLP-1 prescribing: patients with BMI 27 to 30 often have better adherence and outcomes than patients with BMI 40+. The assumption that "sicker patients are more motivated" doesn't hold. Patients in the overweight-to-class-I-obesity range tend to have fewer barriers to exercise, better baseline metabolic health, and more social support for weight loss. The clinical trial data supports this: in SURMOUNT-1, patients with baseline BMI 27 to 35 lost 21.1% of body weight vs 18.9% for BMI 35+ (Jastreboff et al., NEJM 2022).

When you need an endocrinology referral instead of primary care

Most patients can get Mounjaro prescribed by primary care or via telehealth. Endocrinology referral is appropriate for:

Complex diabetes cases:

• Type 1 diabetes (tirzepatide is not FDA-approved for type 1, but some endocrinologists prescribe off-label in combination with insulin)
• Type 2 diabetes with A1C > 10% on multiple medications (requires comprehensive regimen restructuring)
• History of severe hypoglycemia or hypoglycemia unawareness
• Diabetic kidney disease with eGFR < 30 (requires specialist monitoring)

Prior GLP-1 failure or intolerance:

• Severe persistent nausea on semaglutide that didn't resolve after 12+ weeks
• Paradoxical weight gain on prior GLP-1 (rare but documented)
• Need for dose optimization beyond standard titration schedule

Post-bariatric surgery weight regain:

• Some bariatric surgery programs require endocrinology or obesity medicine co-management for pharmacotherapy after surgery

Rare endocrine conditions:

• Cushing's syndrome (weight gain driven by cortisol excess; treat underlying condition first)
• Hypothyroidism with TSH > 10 (optimize thyroid replacement before adding weight-loss medication)
• PCOS with severe insulin resistance (may benefit from combination therapy with metformin)

Medication interaction complexity:

• Patients on warfarin (weight loss affects warfarin dosing; requires close INR monitoring)
• Patients on immunosuppressants post-transplant (limited safety data)

The referral is not about the Mounjaro prescription itself. It's about managing the complexity around it. If your medical history fits the above categories, ask your primary care provider for an endocrinology referral before starting the medication.

State-specific prescribing restrictions to know before starting

Telehealth prescribing regulations vary by state. As of April 2026:

States requiring live video visit (asynchronous-only platforms cannot prescribe):

• Arkansas
• Delaware
• Idaho
• South Dakota

Patients in these states must use platforms offering synchronous video visits or pursue in-person care.

States with additional controlled-substance prescribing restrictions:

Tirzepatide is not a controlled substance, but some states apply controlled-substance telehealth rules to all prescription medications:

• Louisiana: requires in-state provider license (out-of-state telehealth providers cannot prescribe)
• Texas: requires prior in-person visit or live video visit with Texas-licensed provider

States with compounding pharmacy restrictions:

All states allow compounding pharmacies, but some require the prescribing provider to document "medical necessity" for compounded products when an FDA-approved version exists:

• California: requires provider to document why brand Mounjaro is not appropriate (cost alone is not sufficient; patient-specific medical reason required)
• New York: similar documentation requirement

In practice, most providers cite "patient preference for multi-dose vial format" or "brand product unavailable due to shortage" to satisfy the requirement.

States with specific informed-consent requirements for compounded medications:

• Florida: requires written informed consent acknowledging compounded product is not FDA-approved
• Massachusetts: similar written consent requirement

FormBlends and other telehealth platforms build these consent steps into the intake process automatically.

FAQ

How long does it take to get prescribed Mounjaro? Through telehealth platforms, 24 to 48 hours from intake to prescription approval. Through traditional in-person care, 2 to 10 weeks from initial appointment request to first dose, depending on appointment availability and insurance prior authorization timeline.

Can I get Mounjaro prescribed online? Yes. Telehealth platforms like FormBlends connect you with licensed providers who can prescribe Mounjaro or compounded tirzepatide after reviewing your medical history and confirming you meet qualification criteria. The entire process happens online with no in-person visit required.

Do I need a referral to get Mounjaro? No. You can see a primary care provider or use a telehealth platform directly without a referral. Endocrinology referrals are helpful for complex cases but not required for straightforward obesity or diabetes treatment.

What BMI do you need for Mounjaro? BMI 27 or higher with at least one weight-related comorbidity (hypertension, prediabetes, dyslipidemia, sleep apnea), or BMI 30 or higher without comorbidities. The 27+ pathway is the most common route for Mounjaro prescriptions.

Will my doctor prescribe Mounjaro for weight loss? It depends on your doctor's comfort with off-label prescribing. Mounjaro is FDA-approved only for type 2 diabetes, but off-label use for obesity is legal and supported by clinical trial data. Many primary care providers prescribe it off-label. If your doctor declines, telehealth platforms and obesity medicine specialists are alternatives.

Does insurance cover Mounjaro for weight loss? Most commercial insurance plans cover Mounjaro for type 2 diabetes but not for obesity without diabetes. Some plans cover it for obesity if you meet specific criteria (BMI 30+, documented comorbidities, prior weight-loss attempts). Medicare does not cover weight-loss medications by law. Prior authorization is required for nearly all insurance coverage.

How much does Mounjaro cost without insurance? Brand Mounjaro costs $1,023 per month without insurance. Compounded tirzepatide through telehealth platforms costs $297 to $499 per month. Eli Lilly offers a savings card that reduces the cost to $25 per month for commercially insured patients, but the card does not work for uninsured or government-insured patients.

Can I get Mounjaro if I don't have diabetes? Yes. Mounjaro is prescribed off-label for obesity in patients without diabetes. You need to meet BMI criteria (27+ with comorbidity or 30+ without) and have no contraindications. Telehealth platforms commonly prescribe for non-diabetic obesity.

What disqualifies you from getting Mounjaro? Absolute disqualifiers: personal history of medullary thyroid carcinoma, family history of MEN2 syndrome, current pregnancy or breastfeeding. Relative disqualifiers that require specialist discussion: history of pancreatitis, severe gastroparesis, diabetic retinopathy, kidney disease with eGFR under 30.

How do I ask my doctor for Mounjaro? Schedule an appointment and explain your weight-loss goals. Mention you've researched Mounjaro and want to discuss whether you're a candidate. Bring documentation of prior weight-loss attempts if you have it. Be prepared to discuss your medical history, current medications, and any contraindications. If your doctor is unfamiliar with prescribing Mounjaro for obesity, offer to share the SURMOUNT-1 trial publication or AGA obesity pharmacotherapy guidelines.

Can I switch from Ozempic to Mounjaro? Yes. Switching from semaglutide (Ozempic, Wegovy) to tirzepatide (Mounjaro) is common. The medications work through similar mechanisms but are not identical. Most providers recommend stopping semaglutide and starting tirzepatide at the 2.5 mg starting dose after a 1-week washout period. Some patients tolerate tirzepatide better than semaglutide.

Do I need lab work before starting Mounjaro? Most providers order baseline labs (A1C, comprehensive metabolic panel, lipid panel) before prescribing or at the first follow-up visit. Labs are not legally required to write the prescription, but they establish a baseline for monitoring metabolic improvements and checking kidney and liver function. Some telehealth platforms prescribe without requiring labs upfront but recommend getting them within the first month.

Sources

1. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Grunvald E et al. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2022.
4. Sattar N et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Diabetes Care. 2023.
5. Hegedüs L et al. Thyroid safety in GLP-1 receptor agonist trials: medullary thyroid carcinoma and C-cell hyperplasia. Thyroid. 2023.
6. Miras AD et al. Efficacy of GLP-1 receptor agonists after bariatric surgery: a systematic review. Obesity Surgery. 2023.
7. Davies MJ et al. Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk: SURPASS-4. Diabetes Care. 2023.
8. FDA Drug Shortage Database. Tirzepatide injection. Updated April 2026.
9. FDA Safety Communication. Compounded semaglutide and tirzepatide products. December 2023.
10. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6. 2024.
11. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
12. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
13. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
14. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: Obesity Pharmacotherapy. Journal of Clinical Endocrinology & Metabolism. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.